{
    "clinical_study": {
        "@rank": "166717", 
        "brief_summary": {
            "textblock": "OBJECTIVES:\n\n      I.  Determine the dose of recombinant human insulin-like growth factor I that minimizes or\n      decreases the need for exogenous glucose support without causing hypoglycemia."
        }, 
        "brief_title": "Dose Ranging Study of Recombinant Human Insulin-Like Growth Factor I in Children With Hyperinsulinism", 
        "condition": "Hyperinsulinism", 
        "condition_browse": {
            "mesh_term": "Hyperinsulinism"
        }, 
        "detailed_description": {
            "textblock": "PROTOCOL OUTLINE: This is a dose escalation study. Patients receive an escalating dose of\n      recombinant human insulin-like growth factor I (IGF-I).  IGF-I is given subcutaneously twice\n      a day.  The dose of IGF-I is increased each day for 4 days.  Glucose is administered\n      intravenously, when necessary, to prevent hypoglycemia.\n\n      Following the study treatment patients resume prior medication and may undergo surgery."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "PROTOCOL ENTRY CRITERIA:\n\n        --Disease Characteristics--\n\n          -  Diagnosis of hyperinsulinism (i.e., evidence of fasting hypoglycemia with inadequate\n             suppression of insulin, normal pituitary and adrenal function, and increased insulin\n             action)\n\n          -  Intractable hypoglycemia (i.e., persistent IV glucose requirement for maintaining\n             glucose levels greater than 60 mg/dL)\n\n          -  Failed standard treatment regimen of diazoxide, octreotide, and frequent feedings to\n             control hypoglycemia\n\n          -  No other major medical problems"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "3 Months", 
            "minimum_age": "N/A"
        }, 
        "enrollment": "8", 
        "firstreceived_date": "February 24, 2000", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00004699", 
            "org_study_id": "199/13381", 
            "secondary_id": "CHP-FDR001181-DR"
        }, 
        "intervention": {
            "intervention_name": "insulin-like growth factor I", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": [
                "Complement Factor I", 
                "Mitogens", 
                "Insulin"
            ]
        }, 
        "keyword": [
            "endocrine disorders", 
            "hyperinsulinism", 
            "rare disease"
        ], 
        "lastchanged_date": "June 23, 2005", 
        "overall_official": {
            "affiliation": "Children's Hospital of Philadelphia", 
            "last_name": "Pinchas Cohen", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Federal Government"
        }, 
        "phase": "N/A", 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00004699"
        }, 
        "source": "FDA Office of Orphan Products Development", 
        "sponsors": {
            "collaborator": {
                "agency": "Children's Hospital of Philadelphia", 
                "agency_class": "Other"
            }, 
            "lead_sponsor": {
                "agency": "FDA Office of Orphan Products Development", 
                "agency_class": "U.S. Fed"
            }
        }, 
        "start_date": "May 1998", 
        "study_design": "Endpoint Classification: Efficacy Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 1999"
    }, 
    "geocoordinates": {}
}